相关实验视频

Updated: Jul 27, 2025

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

德菲洛克萨明有可能改善糖尿病患者的COVID-19相关炎症反应

Motahareh Zeinivand^1,2, Masoomeh Sharifi^3,4, Gholamhossein Hassanshahi^5,6

¹Department of Physiology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.

International journal of peptide research and therapeutics

|June 5, 2023

概括

管理COVID-19糖尿病患者的铁过载可能是一个早期的治疗策略. 铁化剂德菲洛克萨 (DFO) 被提议通过限制炎症和病毒复制来对抗严重急性呼吸系统综合征冠状病毒2 (SARS-CoV-2).

科学领域:

* 传染病和病毒学
* 血液学和免疫学

背景情况:

*由SARS-CoV-2引起的COVID-19大流行,除了支持性护理之外,缺乏有效的治疗方法.
* 糖尿病和其他慢性疾病患者面临更大的脆弱性和严重的COVID-19结果.
* 严重的COVID-19与炎症加剧有关,由高C反应蛋白,IL-6,铁和费里水平表明.

研究的目的:

* 探索铁恒温失衡在加剧SARS-CoV-2感染中的作用.
* 建议铁化作为COVID-19的潜在治疗策略,特别是在糖尿病患者中.
* 审查Deferoxamine (DFO) 作为一种有效的铁化剂,用于控制COVID-19相关的炎症和病毒复制.

主要方法:

* 关于COVID-19病理生理学,铁代谢和炎症的当前文献的综述.
*分析严重COVID-19病例中的实验室发现,重点关注与铁相关的标记物.
* 评估Deferoxamine (DFO) 作为一种潜在的治疗剂,基于其铁化特性.

主要成果:

*在严重的COVID-19中,炎症导致铁平衡失衡和铁过载.
*SARS-CoV-2需要铁才能复制和激活.
* 管理铁过载可能会减轻COVID-19患者致命的炎症反应.

结论:

* 铁过载是COVID-19严重性的关键因素,特别是在糖尿病患者中.
* 准铁失调是一种有希望的治疗途径,用于COVID-19管理.
*德菲洛克萨明 (DFO) 显示出作为早期治疗干预措施的潜力,以限制COVID-19的严重程度.

关键词:

在 COVID-19 疫情中,德费洛克萨明 (Deferoxamine) 是一种药物.糖尿病糖尿病糖尿病费里氨酸 (Ferritin) 是一种铁素.炎症反应是一种炎症反应.铁过载是因为铁过载.

更多相关视频

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

相关概念视频

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Diabetes: Management and Pharmacotherapy

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

COPD: Management Using Bronchodilators and Corticosteroids

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...

Pathophysiology of Diabetes

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...